Stocks · News reference
Niagen Bioscience Highlights Preclinical Research Linking CD38-Driven NAD+ Depletion To Placental Aging; NOTE: Niagen Bioscience Did Not Conduct, Fund, Or Design This Study, And The NR Used Was Not The Company’s Niagen Ingredient
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience (NASDAQ:NAGE) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Niagen Bioscience Announces Online And Retail Availability Of Tru Niagen At GNC And Sam's Club Locations Across 44 States